Which of the following are true of the FDA?

The statement that all of the choices are true is accurate because it encompasses several aspects of the FDA's role and guidelines in the context of MRI safety and medication use.

The FDA indeed requires that medication guides are provided to patients receiving gadolinium contrast agents. This is important for informing patients about potential risks, benefits, and side effects associated with the use of gadolinium-based contrast agents in MRI scans. Providing these guides helps ensure that patients are fully informed and can make educated decisions regarding their healthcare.

Furthermore, the FDA does not specifically define the terms "normal mode" and "first-level controlled operation mode" limits within their regulation framework. This lack of a defined standard means that manufacturers and clinicians must rely on other guidelines, or develop their protocols for ensuring safety in MRI environments.

Lastly, the FDA recommends specific guidelines for whole-body specific absorption rate (SAR) limits, including that these should be averaged over a timeframe, typically 10 minutes, which is important to consider when evaluating patient safety during MRI procedures. These SAR limits are essential for minimizing the risk of heating in tissues due to RF energy absorbed during MRI scans.

Overall, these points together confirm the accuracy of the assertion that all the statements regarding the FDA are true, highlighting their regulatory role